Online:
Visits:
Stories:
Profile image
By marketresearchnest
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Rabies Therapeutics Market Pipeline Review H1 2017

Thursday, May 18, 2017 4:54
% of readers think this story is Fact. Add your two cents.

(Before It's News)

MarketResearchNest.com adds “Rabies – Pipeline Review, H1 2017” new report to its research database. The report spread across in multiple pages with table and figures in it.

 

Latest Pharmaceutical and Healthcare disease pipeline guide Rabies – Pipeline Review, H1 2017, provides an overview of the Rabies (Infectious Disease) pipeline landscape.

Rabies is a deadly virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. Symptoms include loss of feeling in an area of the body, loss of muscle function, swallowing difficult, excitability, fever and convulsions. The predisposing factors include exposure to wildlife and exposure to other pets that may not be vaccinated.

Browse full table of contents and data tables at https://www.marketresearchnest.com/rabies-pipeline-review-h1-2017.html

The Rabies (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rabies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 2, 10, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Rabies (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

Rabies – Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Celltrion Inc

Curevac AG

Humabs BioMed SA

Indian Immunologicals Ltd

Kamada Ltd

Molecular Targeting Technologies Inc

NanoViricides Inc

Novavax Inc

PaxVax Inc

Sanofi Pasteur SA

Synermore Biologics Co Ltd

Trellis Bioscience Inc

VBI Vaccines Inc

Zydus Cadila Healthcare Ltd

 

Order a Purchase Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=205670

 

Featured News & Press Releases
Jan 11, 2017: CureVac Provides Clinical Update on CV7201 at 35th Annual J.P. Morgan Healthcare Conference
Jan 04, 2017: US FDA Grants Orphan Drug Designation to Yisheng Biopharma’s PIKA Rabies Vaccine
Nov 07, 2016: Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin as a Post-Exposure Treatment
Sep 01, 2016: Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment
Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant
Dec 23, 2015: Kamada’s Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment
Mar 23, 2015: Yisheng Biopharma develops new therapeutic vaccine for rabies
Mar 04, 2014: Kamada Completes Enrollment in U.S. Pivotal Clinical Trial with KamRAB as a Post-Exposure Treatment for Rabies
Aug 28, 2009: Rabies Vaccine Supply Update: IMOVAX Rabies Vaccine Availability
Jul 15, 2008: Kamada Gains Approval of KamRAB in Israel
Oct 23, 2007: Kamada Awarded Another Contract To Deliver Its KamRAB Anti-rabies Vaccination To Latin America
May 01, 2007: Kamada Obtains FDA Approval to Commence Phase II and III Clinical Trials For Its KamRAB Anti-rabies Passive Immunization Product
Sep 18, 2003: Molecular Targeting Technologies, Inc. Forms Partnership With North China Pharmaceutical Company

 

Scope of this Report

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rabies (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Rabies (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rabies (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rabies (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rabies (Infectious Disease)

 

Request Sample Copy at https://www.marketresearchnest.com/requestsample.php?reportid=205670

 

About Us:                         

MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.

 

Contact Us

Mr. Jeet Jain

Sales Manager

[email protected]

+1-240-284-8070

Connect with us:  Google+ | LinkedIn | Twitter | Facebook

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.